Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Apr 8, 2008

NextGen Acquires Pending Patent from Oxon Life Science Linked to Breast Cancer Stem Cells

  • NextGen Bioscience has obtained use, commercialization, and ownership rights of Oxon Life Science’s patent application related to cancer stem cells.

    The application describes an improved method of identifying and purifying undifferentiated stem cells from solid breast carcinomas that are usually resistant to conventional therapies, the companies explain.

    “Based on evidence that cancers such as breast cancer and prostate cancer proliferate primarily from cancer stem cells, this technology will be vital for both early diagnosis and identifying targets for a new generation of targeted therapeutic strategies,” notes NextGen CEO, Konstantinos Kardiasmenos.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »